Bristol-Myers Squibb (BMY) Tops Q3 EPS by 11c; lifts outlook
Tweet
Share
E-mail
Get Alerts BMY Hot Sheet
Price: $54.70 +1.30%
EPS Growth %: +10.3%
Financial Fact:
Other (income)/expense: -224M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +10.3%
Financial Fact:
Other (income)/expense: -224M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Bristol-Myers Squibb (NYSE: BMY) reported Q3 EPS of $1.63, $0.11 better than the analyst estimate of $1.52. Revenue for the quarter came in at $12.2 billion versus the consensus estimate of $11.8 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2025 EPS of $6.40-$6.60, versus the consensus of $6.36. Bristol-Myers Squibb sees FY2025 revenue of $47.5-48 billion, versus the consensus of $47.34 billion.
For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Primoris cuts 2026 outlook on renewables cost overruns, COO exits
- Eledon Pharamceuticals (ELDN) PT Raised to $7 at Leerink
- A. O. Smith CEO Stephen Shafer named chairman
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
